The global allergy diagnostics market size in 2026 is witnessing steady expansion as the prevalence of allergic conditions increases and healthcare providers place greater emphasis on accurate and timely diagnosis. According to Fortune Business Insights, the global allergy diagnostics market size was valued at USD 7.69 billion in 2025 and is projected to grow from USD 8.24 billion in 2026 to USD 14.36 billion by 2034, exhibiting a CAGR of 7.2% during the forecast period. North America dominated the allergy diagnostics market with a market share of 38.36% in 2025.
Allergy diagnostics refers to tests and methods used to identify specific allergens responsible for an immune system overreaction. The increasing prevalence of allergic diseases, rising diagnostic volumes, expanding healthcare infrastructure, and growing awareness regarding the benefits of allergy testing are contributing to market expansion. Technological advancements introduced by leading companies are also supporting the adoption of advanced allergy diagnostic solutions.
The growing occurrence of allergic conditions, including eczema, hay fever, asthma, food allergies, and drug allergies, is increasing the demand for diagnostic procedures. Healthcare professionals increasingly rely on allergy testing to identify specific allergens and support appropriate patient management. The availability of different diagnostic approaches, including in vivo and in vitro testing, is expanding the options available to healthcare providers and patients.
A major development within the market is the increasing adoption of in-vitro allergy diagnostics and automated testing devices. Serum-specific IgE testing kits are gaining attention due to their accuracy, improved safety, and compatibility with high-throughput laboratory environments. Automated immunoassay analyzers and multiplex testing platforms allow laboratories to process larger volumes of patient samples with reduced manual intervention.
These technological developments are also supporting component-resolved diagnostics, which enables the identification of specific allergens responsible for allergic reactions. The increasing integration of automation and advanced diagnostic technologies is expected to strengthen the role of allergy diagnostics across clinical laboratories and healthcare settings.
The increasing prevalence of allergic diseases is a major factor driving the allergy diagnostics market. Growing numbers of patients affected by eczema, hay fever, asthma, food allergies, and other allergic conditions are contributing to an increase in diagnostic procedures. Rising healthcare awareness and the growing adoption of multiplex allergen testing technologies are also supporting market growth.
The development and introduction of novel allergy diagnostic devices by key companies are further supporting market expansion. Increasing research and development activities are encouraging the development of advanced testing solutions that can improve diagnostic efficiency and support more detailed allergen identification.
However, the high cost of advanced allergy diagnostic tests remains a major restraint. Multiplex allergen testing platforms, automated immunoassay analyzers, and component-resolved diagnostics require significant capital investment, in addition to ongoing costs associated with consumables and maintenance. Specialized clinical laboratories and trained professionals may also be required for certain advanced tests, creating additional financial challenges for healthcare facilities.
The competitive landscape of the allergy diagnostics market is supported by increasing product launches, technological development, collaborations, and the expansion of diagnostic laboratory capabilities. Thermo Fisher Scientific Inc. and Siemens Healthineers AG are identified as major companies in the market in 2025.
Key companies are strengthening their market positions through product development, laboratory expansion, collaborations, and improvements in diagnostic technologies. In March 2026, Thermo Fisher Scientific Inc. established a new 8,000-square-meter distribution and labeling center supporting its immunodiagnostics business in Uppsala. Other companies, including Canon Medical Systems Corporation, are also strengthening their presence through collaborations.